Explore the Agenda
8:30 am Morning Coffee and Check-in
9:25 am Chair’s Opening Remarks
Learning the Success Behind PD1 x VEGF & PD-L1 x VEGF by Dissecting the Target Biology & Mechanism of Action
9:30 am Overviewing the Biology of the Targets PD1-VEGF & Their Interactions at a Cellular & Molecular Level to Help Tailor the Bispecific Format
- Examining the biology of the combination target PD1-VEGF and how the design and cellular interactions can be used to tailor the Bispecific format
- Understanding how the initial design of PD1-VEGF was chosen by understanding the biology of the molecule – looking at data for this with different Bispecifics
- Exploring the specific combination of antibodies used in PD1-VEGF and why this combination was chosen, whilst considering their biology
10:00 am Investigating How Simultaneous Targeting of VEGF, PD-L1 & CTLA4 Reshapes the Tumor Microenvironment to Outline Modes of Action & Safety Considerations For Your Bispecifics
- Exploring the immunomodulatory effects of VEGF targeting that synergize with known antiangiogenic effects and inform safety considerations for its targeting
- Dissecting the multimodal mechanism induced by multitargeting strategy to understand how simultaneous targeting of axes present in diverse cell types in the tumor microenvironment can alter the cytokine landscape and ultimately rewire key effector and suppressive cell types: considerations of efficacy and safety
- Assessing the practicality of using bispecifics for membrane-bound and soluble targets: Exploring the potential benefits and challenges of how multitargeting strategies can best tackle the underlying immunobiology
10:30 am Morning Break & Speed Networking
The ideal opportunity to get face-to-face with many of the brightest minds working in the bispecific field and introduce yourself to the attendees that you would like to have more in-depth conversations with.
Leveraging Valuable Preclinical, Clinical, & Safety Data to Gain Key Learnings for PD-L1 x VEGF & Apply These Understandings to Address Current Mechanistic Gaps
11:30 am OTP-01 (Jankistomig), A Unique Dual Paratopic Antibody that Bifunctionally Inhibits PD-1 and VEGFR2
- Structural differentiation: Unlike head-to-tail bispecifics, OTP-01 is a standard effector-null IgG1 that possesses a unique dual-paratopic Fab with overlapping binding sites that co-engage PD-1 and VEGFR2 in a single arm
- Functional differentiation: Leveraging a standard IgG1 backbone, OTP-01 potently and cooperatively engages both targets to enhance tumor biodistribution, while simultaneously neutralizing – VEGF-A/C/D signalling to optimally remodel the TME and curb resistance
- Clinical trajectory: OTP-01 is now in IND-enabling studies, with IND submission targeted for late 2025
12:00 pm Bridging Bench & Bedside for PD-1 x VEGF & PD-L1 x VEGF Bispecifics: Translational Strategy, Format Optimization & Combination Approaches
As PD-1 x VEGF and PD-L1 x VEGF bispecifics progress through preclinical and early clinical pipelines, developers are
challenged to refine therapeutic design, clarify mechanisms of synergy, and anticipate translational hurdles. This roundtable will bring together expert voices and engaged attendees to explore what it will take to successfully advance the bispecific and other bispecifics using similar logic to clinical impact.
- How can target biology guide decisions on bispecific format, affinity tuning, and spatial delivery?
- What insights and programs help us define meaningful biomarkers and pharmacodynamic readouts?
- How can we rationally combine these bispecifics with other immunotherapies or modalities like ADCs and cytokines?
- What are the biggest translational blind spots (e.g., preclinical models) holding back predictive development?
- How do we de-risk safety in multitargeting strategies, especially when soluble and membrane-bound targets are involved?
12:45 pm Lunch Break
Expanding beyond PD1 x VEGF to PD1/PDL1 Targeted Bispecifics – Advancing Targeted Cytokine Strategies with Bispecific Constructs
1:45 pm Designing Targeted Cytokines: Preclinical Lessons from PD-1/PD-L1- Directed IL-15 Bispecifics
- SAR445710 (KD033) a trans-presented high affinity IL-15 vs SAR445877 (KD050) a cispresented reduced affinity IL-15
- Reviewing pre-clinical in vitro and in vivo pharmacology data
- Exploring broader design considerations for targeted cytokines in oncology and beyond
2:15 pm From Bench to Bedside: Early Phase Clinical Insights Into SAR445710 (KD033) and SAR445877 (KD050), Distinct Cytokines Targeting PDL1 or PD1
- Reviewing Phase I safety, pharmacokinetic, pharmacodynamic, and preliminary efficacy data
- Understanding the translational relevance of preclinical findings in clinical settings
- Looking to future directions for PD-1/PD-L1-targeting cytokines in immune-oncology pipelines